This ability to halt or inhibit actions, known as response inhibition ... how different parts of the brain collaborate to regulate inhibitory control. Their findings revealed a four-step neural ...

They discovered that the two immune checkpoint inhibitors combination regimens have different mechanisms of action mediated through different effects on CD4 T cells. The anti-PD-1/LAG-3 drug ...

ACE inhibitors are classified as either short-acting or long-acting, depending on their duration of action. Both can be effective therapy options; however, long-acting ACE inhibitors offer the ...

Researchers from GSK plc presented the discovery and preclinical characterization of novel potent and selective inhaled phosphatidylinositol 4-kinase β (PI4Kβ) inhibitor being developed for the ...

When this inhibitory action is lost, as happens in people with frontal lobe damage, these multiple possibilities become a burden, and can lead to so-called utilization behaviors. Such impaired ...

The first therapies to target this pathway were BRAF inhibitors, but intrinsic and acquired tumor resistance quickly led to treatment failure by reactivation of the MAPK pathway. MEK inhibitors ...

Vividion Therapeutics Inc. has disclosed VVD-065, a novel, first-in-class, allosteric molecular glue of the KEAP1-CUL3 E3-ligase complex, for the potential treatment of NRF2-activated cancers. NRF2 ...

NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDKs, prolonged pharmacodynamic effects, and a distinct mechanism of action.

An investigational drug with the same novel CDK inhibitor action, palbociclib (Pfizer) was also highlighted at this meeting, with data from a phase 2 trial described as promising. Presenting the ...